117 related articles for article (PubMed ID: 38906172)
1. Vinblastine/prednisolone chemotherapy leads to hematological toxicity in dogs with high-grade or metastatic mast cell tumors.
Soussa RW; Jaderberg S; Williams TL; Dobson JM
J Am Vet Med Assoc; 2024 Jun; ():1-9. PubMed ID: 38906172
[TBL] [Abstract][Full Text] [Related]
2. Haematologic toxicity in dogs with mast cell tumours treated with vinblastine/prednisolone chemotherapy with/without radiotherapy.
Stiborova K; Treggiari E; Amores-Fuster I; Del Busto I; Killick D; Maddox T; Marrington M; Mason SL; Blackwood L
J Small Anim Pract; 2019 Sep; 60(9):534-542. PubMed ID: 31245847
[TBL] [Abstract][Full Text] [Related]
3. Tolerability of a rapid-escalation vinblastine-prednisolone protocol in dogs with mast cell tumours.
Serra Varela JC; Pecceu E; Handel I; Lawrence J
Vet Med Sci; 2016 Nov; 2(4):266-280. PubMed ID: 29067202
[TBL] [Abstract][Full Text] [Related]
4. A phase II study to evaluate the toxicity and efficacy of alternating CCNU and high-dose vinblastine and prednisone (CVP) for treatment of dogs with high-grade, metastatic or nonresectable mast cell tumours.
Rassnick KM; Bailey DB; Russell DS; Flory AB; Kiselow MA; Intile JL; Malone EK; Balkman CE; Barnard SM
Vet Comp Oncol; 2010 Jun; 8(2):138-52. PubMed ID: 20579327
[TBL] [Abstract][Full Text] [Related]
5. Adverse haematological effects of vinblastine, prednisolone and cimetidine treatment: a retrospective study in fourteen dogs with mast cell tumours.
Trumel C; Bourgès-Abella N; Touron C; Lanore D; Geffré A; Diquelou A; Guelfi JF; Braun JP
J Vet Med A Physiol Pathol Clin Med; 2005 Aug; 52(6):275-9. PubMed ID: 16050908
[TBL] [Abstract][Full Text] [Related]
6. A phase II clinical trial of vinorelbine in dogs with cutaneous mast cell tumors.
Grant IA; Rodriguez CO; Kent MS; Sfilgoi G; Gordon I; Davis G; Lord L; London CA
J Vet Intern Med; 2008; 22(2):388-93. PubMed ID: 18312556
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of prognostic markers for canine mast cell tumors treated with vinblastine and prednisone.
Webster JD; Yuzbasiyan-Gurkan V; Thamm DH; Hamilton E; Kiupel M
BMC Vet Res; 2008 Aug; 4():32. PubMed ID: 18700956
[TBL] [Abstract][Full Text] [Related]
8. Imatinib Mesylate for the Treatment of Canine Mast Cell Tumors: Assessment of the Response and Adverse Events in Comparison with the Conventional Therapy with Vinblastine and Prednisone.
Macedo TR; de Queiroz GF; Casagrande TAC; Alexandre PA; Brandão PE; Fukumasu H; Melo SR; Dagli MLZ; Pinto ACBCF; Matera JM
Cells; 2022 Feb; 11(3):. PubMed ID: 35159380
[TBL] [Abstract][Full Text] [Related]
9. Comparison of 2- and 3-category histologic grading systems for predicting the presence of metastasis at the time of initial evaluation in dogs with cutaneous mast cell tumors: 386 cases (2009-2014).
Stefanello D; Buracco P; Sabattini S; Finotello R; Giudice C; Grieco V; Iussich S; Tursi M; Scase T; Di Palma S; Bettini G; Ferrari R; Martano M; Gattino F; Marrington M; Mazzola M; Elisabetta Vasconi M; Annoni M; Marconato L
J Am Vet Med Assoc; 2015 Apr; 246(7):765-9. PubMed ID: 25794126
[TBL] [Abstract][Full Text] [Related]
10. Vinblastine and prednisolone as adjunctive therapy for canine cutaneous mast cell tumors.
Davies DR; Wyatt KM; Jardine JE; Robertson ID; Irwin PJ
J Am Anim Hosp Assoc; 2004; 40(2):124-30. PubMed ID: 15007048
[TBL] [Abstract][Full Text] [Related]
11. Combination vinblastine and palladia for high-grade and metastatic mast cell tumors in dogs.
Todd JE; Nguyen SM; White J; Langova V; Thomas PM; Tzannes S
Can Vet J; 2021 Dec; 62(12):1335-1340. PubMed ID: 34857971
[TBL] [Abstract][Full Text] [Related]
12. Principles of treatment for mast cell tumors.
Govier SM
Clin Tech Small Anim Pract; 2003 May; 18(2):103-6. PubMed ID: 12831070
[TBL] [Abstract][Full Text] [Related]
13. Lomustine (CCNU) and prednisone chemotherapy for high-grade completely excised canine mast cell tumors.
Hay JK; Larson VS
Can Vet J; 2019 Dec; 60(12):1326-1330. PubMed ID: 31814640
[TBL] [Abstract][Full Text] [Related]
14. Pre-operative neoadjuvant vinblastine-prednisolone in canine mast cell tumours: A single-centre retrospective cohort study.
Ossowska M; Picornell JA; Finotello R; Amores-Fuster I; Tanis JB
Vet Comp Oncol; 2023 Sep; 21(3):447-459. PubMed ID: 37183272
[TBL] [Abstract][Full Text] [Related]
15. Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses.
Pfister C; Gravis G; Fléchon A; Soulié M; Guy L; Laguerre B; Mottet N; Joly F; Allory Y; Harter V; Culine S;
Eur Urol; 2021 Feb; 79(2):214-221. PubMed ID: 32868138
[TBL] [Abstract][Full Text] [Related]
16. Analysis of risk factors for canine mast cell tumors based on the Kiupel and Patnaik grading system among dogs with skin tumors.
Martins AL; Carvalho FF; Mesquita JR; Gärtner F; Amorim I
Open Vet J; 2021; 11(4):619-634. PubMed ID: 35070857
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of a multi-agent chemotherapy protocol combining lomustine, procarbazine and prednisolone (LPP) for the treatment of relapsed canine non-Hodgkin high-grade lymphomas.
Tanis JB; Mason SL; Maddox TW; Blackwood L; Killick DR; Amores-Fuster I; Harper A; Finotello R
Vet Comp Oncol; 2018 Sep; 16(3):361-369. PubMed ID: 29380942
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of a novel immunomodulator composed of human chorionic gonadotropin and bacillus Calmette-Guerin for treatment of canine mast cell tumors in clinically affected dogs.
Henry CJ; Downing S; Rosenthal RC; Klein MK; Meleo K; Villamil JA; Fineman LS; McCaw DL; Higginbotham ML; McMichael J
Am J Vet Res; 2007 Nov; 68(11):1246-51. PubMed ID: 17975981
[TBL] [Abstract][Full Text] [Related]
19. Response rate to a single dose of vinblastine administered to dogs with treatment-naive multicentric lymphoma.
Harding K; Bergman N; Smith A; Lindley S; Szivek A; Milner R; Brawner W; Lejeune A
Vet Comp Oncol; 2018 Dec; 16(4):636-641. PubMed ID: 30117260
[TBL] [Abstract][Full Text] [Related]
20. Risk Associated with Severe Hematological Toxicity in Patients with Urothelial Cancer Receiving Combination Chemotherapy of Gemcitabine and Cisplatin.
Takahashi N; Sunaga T; Fujimiya T; Kurihara T; Nagatani A; Yamagishi M; Watanabe T; Sasaki H; Ogawa Y; Sasaki T
Chemotherapy; 2020; 65(1-2):29-34. PubMed ID: 32668429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
